Les pages suivantes contiennent des informations relatives à un projet d’augmentation de capital de Sensorion qui ne ferait l’objet d’une offre réservée qu’en France et dans d’autres pays, à l’exception du Canada, du Japon ou de l’Australie, s’il était réalisé.
Votre Pays
Ce site Internet et les informations qui y figurent ne sont pas destinés et ne doivent pas être consultés par, ni distribués ou envoyés à des personnes résidant ou physiquement présentes aux Etats-Unis d’Amérique (incluant les territoires des Etats-Unis, ci-après les « Etats-Unis »), au Canada, au Japon ou en Australie et ne constituent pas une offre de vente ou de souscription, ni une sollicitation d’une offre d’achat ou de souscription d’actions ou autres titres de Sensorion aux Etats-Unis, au Canada, au Japon ou en Australie. Les actions de Sensorion mentionnées sur ce site Internet n’ont pas été et ne seront pas enregistrés conformément au U.S. Securities Act de 1933, tel qu’amendé (le « U.S. Securities Act ») et ne peuvent être ni offerts ni cédés aux Etats-Unis sans enregistrement ou exemption d’enregistrement conformément au U.S. Securities Act.
Toute personne résidant hors de France et hors des Etats-Unis, du Canada, du Japon et d’Australie, souhaitant avoir accès aux documents contenus sur ce site devra tout d’abord s’assurer qu’il n’existe pas de lois et règlements locaux lui interdisant ou limitant son droit d’accéder à ce site Internet ou requérant un enregistrement ou une autorisation aux fins de lui permettre d’acquérir des titres. Aucun enregistrement ou autorisation de ce type n’a été obtenu et ne sera obtenu hors de France. Sensorion exclut toute responsabilité en cas de violation de la législation et la réglementation applicable par quelque personne que ce soit.
Informations exclusives
Je certifie par conséquent que :
(1) Je suis résident et physiquement présent en France;
Ou
(2) Je suis résident et physiquement présent dans un des Etats Membres de l’Espace Economique Européen (autre que la France) ou au Royaume-Uni soumis aux dispositions du Règlement (UE) 2017/1129 du Parlement européen et du Conseil du 14 juin 2017 (le « Règlement Prospectus ») et je suis un investisseur qualifié au sens du Règlement Prospectus,
Et
(3) Je ne suis ni résident ni physiquement présent aux Etats-Unis, au Canada, au Japon ou en Australie.
J’ai lu et compris cet avertissement et donne les garanties mentionnées ci-dessus de même que j’accepte de respecter les conditions mentionnées ci-dessus
NOUS SOMMES DÉSOLÉS
L'accès à ces informations est strictement réservé aux pays en dehors des Etats-Unis d'Amérique, le Canada, l'Australie et le Japon.
The following pages include information pertaining to a potential capital increase of Sensorion, which would be conducted pursuant to a reserved offering in France and elsewhere outside Canada, Australia and Japan, if it is conducted in the future at all.
Your Country
Exclusive Informations
This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the “United States”), Canada, Japan or Australia, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any shares or other securities of Sensorion in the United States, Canada, Japan or Australia. The shares of Sensorion referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act.
All persons residing outside of France and outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained outside of France. Sensorion assumes no responsibility if there is a violation of applicable law and regulations by any person.
I certify that:
(1) I am a resident of and physically present in France;
Or
(2) I am a resident of and physically present in a Member State of the European Economic Area (other than France) or the United Kingdom which is subject to the provisions of Regulation (EU) 2017/1129 of the European Parliament of the Council of June 14, 2017 (the “Prospectus Regulation”), and I am a qualified investor as defined in the Prospectus Regulation,
And
(3) I am not a resident of or physically present in the United States, Canada, Japan or Australia.
I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions
NOT ALLOWED
Access to this information is strictly reserved for countries outside the United States of America, Canada, Australia and Japan.
The inner ear can be affected by diseases of different origin, which are generally poorly understood. Inner ear damage results in impaired hearing and/or balance, depending on whether the damage is located in the cochlea and/or the vestibule (or labyrinth).
Sudden SensoriNeural Hearing Loss (SSNHL)
SSNHL is also known as sudden deafness and belongs to the group of rare conditions that affect the inner ear. Hearing loss is rapid (instant or in <72 hours) and typically unilateral. The loss is >30 decibels (or a 1000-fold reduction of sound perception). It is often accompanied by tinnitus and vertigo and a significant increase in risk of falling.
SSNHL most commonly affects people over 45 years of age.
SSNHL occurs with the damage or loss of sensory hair cells (sound detectors), the sensory neurons (conducting auditory information to the brain), or their connections.
While the cause of most cases is unknown (idiopathic in 71% of cases), other possible causes include:
infectious (12.8%) or otologic (4.7%) diseases
traumatic injury including noise (4.2%), vascular/hematologic issues (2.8%), neoplasia (2.3%), or other (2.2%)
Ototoxicity and Cisplatin-induced ototoxicity
Ototoxicity is the toxic effect of substances, such as solvents, foods and pharmaceuticals, on the inner ear. Some pharmacologic therapies can affect cochlear or vestibular tissue depending on their sensitivity. When administered orally, intravenously or intramuscularly, drugs spread throughout the body and reach the inner ear, entering the labyrinth liquids, vestibular and cochlear tissues. Substances can then damage the membranes and intracellular organelles of the hair cells. Such damage can lead to symptoms of vertigo, tinnitus and hearing loss, which may even progress to complete deafness.
A wide range of drugs can cause this damage including:
Antibiotics belonging to the aminoglycoside class
Aspirin and some non-steroidal anti-inflammatory drugs
Quinine antimalarial drugs
Platinum salts, including cisplatin, used in chemotherapy
The damage is typically bilateral and is a limiting factor for the chemotherapy, requiring dose-adjustment and occasionally a change in chemotherapy protocol.
Platinum-based agents such as cisplatin, carboplatin and oxaliplatin, alone or in combination, are often used to treat a wide variety of cancers. However, ototoxicity leading to hearing loss and tinnitus is one of the common and often severe adverse effects.
Cisplatin is used in 25% of primary chemotherapeutic treatment of various cancers. Hearing loss with cisplatin is seen in more than 30% of adults and observed to varying degrees in >70% of treated children. The hearing loss is also progressive with each successive chemotherapy cycle and irreversible.
Otoferlin Deficiency
• Otoferlin deficiency is a rare genetic disorder caused by mutations of the OTOF gene. It’s one of the more frequent forms of congenital deafness. Affected babies typically have a bilateral severe to profound hearing loss.
• The Otoferlin protein is the major calcium sensor for synaptic exocytosis in cochlear sensory cells (Inner Hair Cells, IHCs). Thus, it’s essential for transmitting sound information at the auditory sensory cell synapses.
Usher Syndrome Type 1
• Usher Syndrome Type 1 is the most severe expression of Usher Syndrome. It’s caused by various mutations on USH1C, MYO7A, CDH23, PCDH15, USH1G and CIB2 genes. It is characterized by congenital profound deafness and balance defects. Affected patients subsequently undergo sight loss during childhood, leading to blindness.
• Inner hair cells lacking the scaffold protein called Sans, encoded by the USH1G gene, cannot develop, maintain and have a functional hair bundle.